Published in Genes Dev on May 01, 2013
The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature (2015) 2.63
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature (2015) 1.90
Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell (2015) 1.88
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell (2015) 1.51
MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer (2015) 1.47
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep (2014) 1.34
BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment. Dev Cell (2014) 1.28
U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res (2014) 1.13
Widespread intron retention diversifies most cancer transcriptomes. Genome Med (2015) 1.01
High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep (2013) 0.99
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med (2016) 0.97
RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer (2016) 0.92
Optimization of antitumor modulators of pre-mRNA splicing. J Med Chem (2013) 0.91
A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. Elife (2015) 0.89
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res (2015) 0.88
Aptamer identification of brain tumor-initiating cells. Cancer Res (2013) 0.86
Therapeutic targeting of splicing in cancer. Nat Med (2016) 0.85
Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep (2015) 0.84
An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses. PLoS Pathog (2015) 0.81
Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates. Pharmacol Res Perspect (2015) 0.81
The enigmatic ERH protein: its role in cell cycle, RNA splicing and cancer. Protein Cell (2013) 0.80
Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer (2015) 0.80
Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays (2016) 0.77
CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol (2015) 0.76
Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells. Development (2017) 0.76
Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer. Br J Cancer (2016) 0.75
Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis. Int J Mol Med (2016) 0.75
Molecular pathways: regulation and targeting of kinetochore-microtubule attachment in cancer. Clin Cancer Res (2014) 0.75
A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett (2016) 0.75
Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP/TGF-β superfamily as a regulator of XIST expression. Proc Natl Acad Sci U S A (2017) 0.75
Regulation of transcriptional elongation in pluripotency and cell differentiation by the PHD-finger protein Phf5a. Nat Cell Biol (2016) 0.75
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS One (2017) 0.75
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clin Cancer Res (2016) 0.75
Sensitivity to BUB1B inhibition defines an alternative classification of glioblastoma. Cancer Res (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics (2011) 25.76
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol (2010) 22.10
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Pre-mRNA splicing: awash in a sea of proteins. Mol Cell (2003) 8.28
The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem (1996) 7.08
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell (2009) 6.77
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 6.54
Mitotic spindle organization by a plus-end-directed microtubule motor. Nature (1992) 6.52
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature (2009) 5.48
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol (2007) 4.95
A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell (2009) 4.17
Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol (2007) 3.97
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 3.54
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
The human mitotic checkpoint protein BubR1 regulates chromosome-spindle attachments. Nat Cell Biol (2004) 3.27
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Early nonsense: mRNA decay solves a translational problem. Nat Rev Mol Cell Biol (2006) 3.11
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A (2010) 3.08
Glioma stem cells: a midterm exam. Neuron (2008) 2.69
Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev (2011) 2.45
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J (2002) 2.39
It takes a PHD to read the histone code. Cell (2006) 2.34
Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci (2007) 1.88
New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J Antibiot (Tokyo) (1996) 1.87
Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J (2001) 1.83
Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol (2011) 1.77
Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. J Antibiot (Tokyo) (2004) 1.74
Alternative splicing of RNA triplets is often regulated and accelerates proteome evolution. PLoS Biol (2012) 1.71
A class of human exons with predicted distant branch points revealed by analysis of AG dinucleotide exclusion zones. Genome Biol (2006) 1.56
A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res (2005) 1.43
Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep (2012) 1.36
Removal of a single alpha-tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in Saccharomyces cerevisiae. Mol Cell Biol (2002) 1.36
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res (2010) 1.34
Degrade, move, regroup: signaling control of splicing proteins. Trends Biochem Sci (2011) 1.32
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 1.32
Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol (2009) 1.29
Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. J Med Chem (2009) 1.28
Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res (2007) 1.25
PHD fingers: epigenetic effectors and potential drug targets. Mol Interv (2009) 1.21
Antitumor compounds based on a natural product consensus pharmacophore. J Med Chem (2008) 1.17
The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. Virology (2005) 1.08
Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov (2012) 1.07
Ini, a small nuclear protein that enhances the response of the connexin43 gene to estrogen. Endocrinology (2003) 0.93
PHF5A represents a bridge protein between splicing proteins and ATP-dependent helicases and is differentially expressed during mouse spermatogenesis. Cytogenet Genome Res (2008) 0.87
Identification and characterization of a novel murine multigene family containing a PHD-finger-like motif. Biochem Biophys Res Commun (2002) 0.86
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol (2005) 9.12
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Regulation of PTEN by Rho small GTPases. Nat Cell Biol (2005) 4.51
Genome-wide MyoD binding in skeletal muscle cells: a potential for broad cellular reprogramming. Dev Cell (2010) 4.50
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
Wnt and TGF-beta signaling are required for the induction of an in vitro model of primitive streak formation using embryonic stem cells. Proc Natl Acad Sci U S A (2006) 3.85
Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol (2004) 3.67
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell (2013) 3.35
The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res (2004) 3.33
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3. Cell (2013) 3.15
Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis. Nat Methods (2004) 3.01
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Cohesin-mediated interactions organize chromosomal domain architecture. EMBO J (2013) 2.48
Remodeling of DNA methylation and phenotypic and transcriptional changes in synthetic Arabidopsis allotetraploids. Plant Physiol (2002) 2.41
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16
Regulation of thalamocortical patterning and synaptic maturation by NeuroD2. Neuron (2006) 2.15
REST regulates distinct transcriptional networks in embryonic and neural stem cells. PLoS Biol (2008) 2.12
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Zebrafish mutants identify an essential role for laminins in notochord formation. Development (2002) 2.03
Intervertebral disc transplantation in the treatment of degenerative spine disease: a preliminary study. Lancet (2007) 2.01
Comparison of actigraphy and polysomnography to assess effects of zolpidem in a clinical research unit. Sleep Med (2012) 1.91
Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev (2013) 1.88
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest (2004) 1.85
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res (2008) 1.84
Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages. EMBO J (2010) 1.82
Significance testing for small microarray experiments. Stat Med (2005) 1.80
Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion (2010) 1.80
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
Design of highly emissive polymer dot bioconjugates for in vivo tumor targeting. Angew Chem Int Ed Engl (2011) 1.76
Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest Ophthalmol Vis Sci (2004) 1.73
Smarcc1/Baf155 couples self-renewal gene repression with changes in chromatin structure in mouse embryonic stem cells. Stem Cells (2009) 1.72
Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci (2005) 1.68
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res (2006) 1.64
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res (2006) 1.55
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients. J Pediatr (2009) 1.47
Conservation of regional gene expression in mouse and human brain. PLoS Genet (2007) 1.47
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet (2002) 1.45
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep (2013) 1.44
A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Hum Mol Genet (2002) 1.43
PEI-PEG-Chitosan Copolymer Coated Iron Oxide Nanoparticles for Safe Gene Delivery: synthesis, complexation, and transfection. Adv Funct Mater (2009) 1.42
Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet (2005) 1.42
Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet (2002) 1.41
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev (2012) 1.40
Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking. Mol Pharmacol (2004) 1.39
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet (2005) 1.39
Chromatin remodeling around nucleosome-free regions leads to repression of noncoding RNA transcription. Mol Cell Biol (2010) 1.35
Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol (2008) 1.33
Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis (2008) 1.33
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet (2002) 1.33
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg (2005) 1.31
Tools for simulating evolution of aligned genomic regions with integrated parameter estimation. Genome Biol (2008) 1.30
EXPO, an exocyst-positive organelle distinct from multivesicular endosomes and autophagosomes, mediates cytosol to cell wall exocytosis in Arabidopsis and tobacco cells. Plant Cell (2010) 1.30
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
XRate: a fast prototyping, training and annotation tool for phylo-grammars. BMC Bioinformatics (2006) 1.29
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci U S A (2009) 1.26
Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BMC Bioinformatics (2006) 1.24
Wnt activation is implicated in glioblastoma radioresistance. Lab Invest (2011) 1.22
Mitochondrial haplotypes may modulate the phenotypic manifestation of the deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion (2009) 1.19
Health-related quality of life in pediatric liver transplant recipients compared with other chronic disease groups. Pediatr Transplant (2010) 1.19
The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning. Proc Natl Acad Sci U S A (2005) 1.19
A class of models for analyzing GeneChip gene expression analysis array data. BMC Genomics (2005) 1.18
Assessing bias in experiment design for large scale mass spectrometry-based quantitative proteomics. Mol Cell Proteomics (2007) 1.18
Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α⁺ semi-invariant T cells. Blood (2011) 1.16
Characterization of a ViI-like phage specific to Escherichia coli O157:H7. Virol J (2011) 1.16
Synthesis and antitumor activity of novel dithiocarbamate substituted chromones. Eur J Med Chem (2009) 1.16
A novel method for high-level production of TEV protease by superfolder GFP tag. J Biomed Biotechnol (2010) 1.15
Transducers: an emerging probabilistic framework for modeling indels on trees. Bioinformatics (2007) 1.15
Upregulation of acid-sensing ion channel ASIC1a in spinal dorsal horn neurons contributes to inflammatory pain hypersensitivity. J Neurosci (2007) 1.15
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15
Horizontal transfer of expressed genes in a parasitic flowering plant. BMC Genomics (2012) 1.14
Tripotential differentiation of adherently expandable neural stem (NS) cells. PLoS One (2007) 1.13
Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A (2012) 1.13
Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One (2010) 1.13
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Massive mitochondrial gene transfer in a parasitic flowering plant clade. PLoS Genet (2013) 1.12
Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet (2002) 1.09
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09